Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,616.85
(
0.08%
)
US TECH 100
24,198.00
(
2.80%
)
Dow Jones
46,584.46
(
-0.18%
)
Brent Oil
93.61
(
-7.51%
)
Bitcoin
71,465.98
(
-0.74%
)
News Focus
News Focus
Post# of 257369
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122853
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 126139

Sunday, 09/04/2011 12:27:11 PM

Sunday, September 04, 2011 12:27:11 PM

Post# of 257369

Perhaps this puts ANDS' setrobuvir (aka ANA598) in play now. (I'm being entirely facetious of course.) ; )

In all seriousness, the non-nuke class has been a gigantic black hole for developers. Although the non-nuke programs from ANDS, GILD, IDIX, VPHM, and VRTX have gone nowhere, several other companies (ABT, B-I, MRK, PFE) are still trying.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today